Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70
Byron Brook(Boston Children's Hospital), David J. Dowling(Boston Children's Hospital), Soumik Barman(Boston Children's Hospital), Cali Sweitzer(Boston Children's Hospital), Jacob A. Koster(Boston Children's Hospital), Manisha Menon(Boston Children's Hospital), Valérie Duval(Intarcia Therapeutics (United States)), Ofer Levy(Broad Institute), Pallab Ghosh(Indian Institute of Science Bangalore), Etsuro Nanishi(University of Toronto), K. Wade Foster(Intarcia Therapeutics (United States)), Lindsey R. Baden(Brigham and Women's Hospital), Kimia Abedi(Boston Children's Hospital), Lauren Speciner(Intarcia Therapeutics (United States)), Thomas C. VanCott(Intarcia Therapeutics (United States)), Romain Micol(Intarcia Therapeutics (United States)), Asad Khanmohammed(Intarcia Therapeutics (United States))
Cited by 38
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k
SARS-CoV-2 viral load is associated with increased disease severity and mortality
|Nature Communications|2020|981
Influence of Human Immunodeficiency Virus Infection on the Course of Hepatitis C Virus Infection: A Meta‐Analysis
|Clinical Infectious Diseases|2001|969